AEMD — AETHLON MEDICAL INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 882291 ·
Last close
$5.08
Market Cap
$8.17M
52W High
$24.75
52W Low
$1.41
ADV30
45,715
Next earnings
2027-02-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -1,929,296 | -1,884,266 | 6,333,107 | 5,026,458 | 1,446,835 |
| Dec 2025 | 0 | — | -2,062,116 | -2,018,245 | 8,057,128 | 6,956,397 | 1,344,031 |
| Sep 2025 | 0 | — | -1,509,830 | -1,487,100 | 7,323,090 | 5,853,493 | 1,577,113 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,998,392
Investing CF
$141
Financing CF
$6,521,904
CapEx
$-2,051
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-77.39
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-175,106,286
Inventory
—
Receivables
$218,314
ST Investments
—
EBIT TTM
$-7,137,098
Pretax Income TTM
$-7,151,469
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -7,293,631 | -7,151,469 | 6,330,000 | 1,446,835 | 4,886,272 | -6,998,392 |
| Mar 2025 | 0 | -9,341,365 | -13,388,089 | 7,359,534 | 2,236,004 | 5,123,530 | -7,645,532 |
| Mar 2024 | 0 | -12,636,568 | -12,208,174 | 8,245,982 | 2,479,650 | 5,766,332 | -10,129,810 |
| Mar 2023 | 574,245 | -11,898,638 | -12,029,786 | 17,508,940 | 2,444,730 | 15,064,210 | -10,505,128 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$156,534
NetIncome TTM
$-6,937,523
OpCashFlow TTM
—
Assets (Latest)
$6,235,371
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTVA | MetaVia Inc. | $8.24M | $1.25 | — |
| KYNB | KYNTRA BIO, INC. | $8.26M | $2.04 | — |
| VTGN | Vistagen Therapeutics, Inc. | $8.34M | $0.19 | — |
| CALC | CalciMedica, Inc. | $8.41M | $1.22 | — |
| DARE | Dare Bioscience, Inc. | $8.44M | $0.43 | — |
News headlines (Yahoo Finance, 1h cache)
Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
2026-11-12 21:30 · Yahoo
Aethlon Medical Shares Surge Over 400% After Announcing North Immunology Merger
2026-09-17 12:36 · Yahoo
North Immunology joins biotech reverse merger boom with Aethlon deal
2026-09-17 11:09 · Yahoo
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
2026-09-17 10:30 · Yahoo
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
2026-08-13 20:15 · Yahoo
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
2026-07-13 12:01 · Yahoo
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
2026-07-06 13:25 · Yahoo
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
2026-06-26 12:01 · Yahoo
Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...
2026-06-17 01:00 · Yahoo
Aethlon Medical advances Hemopurifier study as final trial cohort nears completion
2026-06-17 16:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.